> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest FDA Warning Letter
- URL: https://www.fdaweb.com/latest-fda-warning-letter-30/
- Published: 2019-10-29T12:00:00.000Z
- Updated: 2026-09-15T01:59:26.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5145369

FDA has posted its latest batch of Warning Letters that includes one medical product company. It can be accessed by clicking on the link following the summary below:

**PetNet Solutions**, Knoxville, TN (10/17): FDA inspected the firm’s Woburn, MA drug manufacturing facility and cited significant GMP violations for positron emission tomography (PET) drugs. For example, the firm’s facilities are not adequate to ensure the prevention of contamination of equipment or product by environmental conditions that could reasonably be expected to have an adverse effect on product quality. PetNet’s laboratory also failed to develop and follow adequate written procedures for testing components, in-process materials, and finished PET drug products to ensure conformance with appropriate standards. The letter also recommended that the company hire a consultant to assist in meeting GMP requirements. To view the letter, click [here](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/petnet-solutions-inc-584016-10172019?ref=fdaweb.com).